MedPath

Comparison of iron kinetics maintenance from Darbepoetin for hemodialysis patients to Epoetin beta pegol administration switching administration and Epoetin beta pegol twice a month as an index hepcidin 25 -ERI (prospective observational study)

Not Applicable
Completed
Conditions
renal anemia
Registration Number
JPRN-jRCT1090220252
Lead Sponsor
shogo kimura
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria

A common selection criteria)
Patients - three times a week hemodialysis have received more than one year
Patients obvious iron deficiency is not observed in-the past three months
- 20 years of age or older patients
Patients who obtained the consent, with respect to the present study
(A group)
DA was administered once a week Hb is 7.1 - 9.9g / dL and the effect inadequate for switching to CERA
Patients were example
Patient - DA dose per week of 10 - 60
(B group)
Patients receiving CERA - twice a monthPatients and one month CERA dose per month of 50 -200
Patients - Hb concentration of the past three months has remained at 10 - 12g / d

Exclusion Criteria

Patient management is insufficient -Hb concentration
(Hb patients <7g / dL or Hb,> 13g / dL has been confirmed)
Hypertensive patients poorly controlled with oral medicine,

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hb,Frt,TSAT,Hep,MCV,at the start of ERI value at the end of ERI value
Secondary Outcome Measures
NameTimeMethod
Target Hb retention rate
© Copyright 2025. All Rights Reserved by MedPath